登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>FOLR1 >FO1-H52H1

Human FOLR1 Protein, His Tag (MALS verified)

分子别名(Synonym)

FOLR-1,FBP,FOLR,FRα

表达区间及表达系统(Source)

Human FOLR1, His Tag (FO1-H52H1) is expressed from human 293 cells (HEK293). It contains AA Arg 25 - Met 233 (Accession # P15328-1).

Predicted N-terminus: Arg 25

Request for sequence

蛋白结构(Molecular Characterization)

FOLR1 Structure

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 26.5 kDa. The protein migrates as 32-40 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

内毒素(Endotoxin)

Less than 0.1 EU per μg by the LAL method.

纯度(Purity)

>95% as determined by SDS-PAGE.

>95% as determined by SEC-MALS.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, pH7.5 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

电泳(SDS-PAGE)

FOLR1 SDS-PAGE

Human FOLR1, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

SEC-MALS

FOLR1 SEC-MALS

The purity of Human FOLR1, His Tag (Cat. No. FO1-H52H1) is more than 95% and the molecular weight of this protein is around 34-55 kDa verified by SEC-MALS.

Report

 

活性(Bioactivity)-ELISA

FOLR1 ELISA

Immobilized Folic Acid-BSA Conjugate at 5 μg/mL (100 μL/well) can bind Human FOLR1, His Tag (Cat. No. FO1-H52H1) with a linear range of 5-78 ng/mL (QC tested).

Protocol

FOLR1 ELISA

Immobilized Human FOLR1, His Tag (Cat. No. FO1-H52H1) at 1 μg/mL (100 μL/well) can bind Anti-FOLR1 Antibody,Mouse IgG1 with a linear range of 0.2-1 ng/mL (QC tested).

Protocol

FOLR1 ELISA

Immobilized Anti-FOLR1 Antibody,Mouse IgG1 at 1 μg/mL (100 μL/well) can bind Human FOLR1, His Tag (Cat. No. FO1-H52H1) with a linear range of 1-5 ng/mL (Routinely tested).

Protocol

 

活性(Bioactivity)-FACS

FOLR1 FACS

2e5 of Anti-FOLR1 CAR-293 cells were stained with 100 μL of 0.3 μg/mL of Human FOLR1, His Tag (Cat. No. FO1-H52H1) and negative control protein respectively, washed and then followed by PE anti-His antibody and analyzed with FACS (Routinely tested).

Protocol

 
评论(15)
  1. 187XXXXXXX1
  2. 6人赞
  3. 经过ELISA试验验证,该抗原具有良好的蛋白活性,可以用于下一步小鼠杂交瘤上清单克隆抗体的筛选和相关的功能验证
  4. >
  5. 2022-6-21
  1. 183XXXXXXX6
  2. 1人赞
  3. 经SPR验证,测单价亲和力,抗人FC芯片,load稀释后抗体,加入稀释后的Folate R,His tag,亲和力常数为0.3 nM。
  4. >
  5. 2022-7-21
  1. 159XXXXXXX5
  2. 0人赞
  3. 此蛋白亲和力特别好,而且比较稳定,在推荐的条件下进行溶解处理,使用时不同批次之间差异很小,在ELISA实验中,不管是用于包被还是标准品都有很好的重现性,后续还会继续使用,而且也会尝试其他蛋白。protocal也很详细,还有赠品,物流也快。
  4. 2023-3-3
 
ACRO质量管理体系
 
 

背景(Background)

Folate Receptor 1 (FOLR1) is also known as Folate receptor alpha, Folate Binding Protein (FBP), FOLR, and is a member of the folate receptor (FOLR) family. Members of this gene family have a high affinity for folic acid and for several reduced folic acid derivatives, and mediate delivery of 5-methyltetrahydrofolate to the interior of cells. Mature FOLR1 is an N-glycosylated protein that is anchored to the cell surface by a GPI linkage. FOLR1 is predominantly expressed on epithelial cells and is dramatically upregulated on many carcinomas. FOLR1 is internalized to the endosomal system where it dissociates from its ligand before recycling to the cell surface. A soluble form of FOLR1 can be proteolytically shed from the cell surface into the serum and breast milk. Defects in FOLR1 are the cause of neurodegeneration due to cerebral folate transport deficiency (NCFTD). NCFTD is an autosomal recessive disorder resulting from brain-specific folate deficiency early in life.

 

前沿进展

FOLR1 as a therapeutic target in platinum-resistant ovarian carcinoma: unique expression patterns across ovarian carcinoma histotypes and molecular subtypes of low-grade serous carcinoma
Leung, Llaurado-Fernandez, Cameron et al
J Gynecol Oncol (2025)
Abstract: With the development of novel antibody-drug conjugates (ADCs), folate receptor alpha (FOLR1) is a promising therapeutic target for the treatment of platinum-resistant tubo-ovarian carcinomas. The main aims of this study were to assess FOLR1 protein expression in a large cohort of ovarian carcinoma histotypes. To inform future clinical trial design we identified molecular correlates of FOLR1 expression in low-grade serous carcinoma (LGSC).One thousand five hundred forty-seven ovarian carcinoma samples from 5 different Canadian cohorts were successfully evaluated by immunohistochemistry for FOLR1 expression using the PS2+ system. Statistical analyses with clinicopathological parameters, LGSC molecular subtypes, and overall survival (OS) were performed.High FOLR1 expression was detected in 44% of high-grade serous carcinomas, and in 30% LGSC, 8% clear cell, 6% endometrioid, and 0% mucinous and/or mesonephric-type adenocarcinomas. In 160 LGSC cases, FOLR1 expression was more frequent in cases with normal MAPK pathway status (37% MAPK wild type vs. 14% canonical MAPK pathway mutations; p=0.002), low progesterone receptor (PR) expression (41%) vs. 23% (Allred score >2; p=0.02), and p16 loss (48% p16 absent vs. 26% normal; p=0.03). Canonical MAPK mutation status and PR expression remained significant on multivariable analysis. No significant associations between OS and FOLR1 expression were observed.A significant proportion of LGSC express high FOLR1 levels supporting the development of clinical trials to investigate ADCs targeting FOLR1 as novel agents for treating this disease. In LGSC, high FOLR1 expression was associated with fewer MAPK pathway alterations, low PR expression, and p16 loss.© 2025. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.
Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody-drug conjugate
Johannet, Flint, Chui et al
Gynecol Oncol (2025) 195, 173-179
Abstract: Mirvetuximab soravtansine-gynx (MIRV) is a FOLR1-binding antibody-drug conjugate (ADC) with a microtubule inhibitor payload. We investigated MIRV's efficacy, toxicity profile, and determinants of resistance in a cohort of patients with recurrent/persistent high FOLR1-expressing high-grade serous ovarian cancer (HGSOC).This retrospective study included 170 patients with recurrent/persistent FOLR1-high (≥75 % of tumor cells with ≥2+ membranous staining intensity) HGSOC who received standard-of-care MIRV monotherapy. We evaluated progression-free survival (PFS) and overall survival (OS) using the Kaplan-Meier method and multivariable Cox proportional hazards models. We classified adverse events using CTCAE v5.0.Overall, median PFS was 3.5 months (95 % CI, 3.0-4.1). However, 22.4 % had PFS ≥6 months and were less likely to have progressed on or within one month of prior taxane-based therapy (P = 0.008). Patients with previous progression on a taxane had worse PFS (HR, 1.69; 95 % CI, 1.19-2.40; P = 0.003) and OS (HR, 2.34; 95 % CI, 1.45-3.77; adjusted P = 0.0005). FOLR1 expression was lower in post-MIRV samples (n = 12; P = 0.005). New or worsening neuropathy was observed in 37.6 % of patients. Among the 34.1 % who experienced ocular toxicity, median onset was 42.5 days. Treatment was discontinued in 5.3 % of patients due to toxicity.MIRV confers meaningful PFS benefit for a subset of individuals with HGSOC. Resistance may be associated with decreased FOLR1 target expression or payload resistance. FOLR1-targeted ADCs with a different payload should be evaluated for patients who progress on MIRV but retain high tumor FOLR1 expression.Copyright © 2025. Published by Elsevier Inc.
Evaluation of Laboratory-Derived Immunohistochemical Assays for Folate Receptor α Expression in Epithelial Ovarian Cancer and Comparison With a Companion Diagnostic
Deutschman, Fulton, Sloss
Arch Pathol Lab Med (2025)
Abstract: The VENTANA FOLR1 (FOLR1-2.1) RxDx (FOLR1 CDx) assay, developed by Roche Tissue Diagnostics, is a Food and Drug Administration-approved immunohistochemical assay intended for use in the assessment of folate receptor α (FRα) expression in formalin-fixed, paraffin-embedded epithelial ovarian, fallopian tube, and primary peritoneal tumor specimens. No published reports have compared the performance of other available FRα antibodies with the approved FOLR1 CDx.To assess the performance of research FRα laboratory-developed tests compared with the FOLR1 CDx.The performance of 6 FRα-targeting antibodies was compared with the approved FOLR1 CDx in normal fallopian tube specimens. Two antibodies were selected for further assessment and compared with the FOLR1 CDx in ovarian tumor specimens.Of the 6 antibodies tested, 4 displayed a lack of specific membrane staining and/or high background, whereas 2 antibodies, produced by Leica Biosystems and Biocare Medical, respectively, exhibited specific and sensitive FRα staining. When assessed for their ability to correctly identify FRα-positive samples (per the FOLR1 CDx label, ≥75% of viable tumor cells with moderate and/or strong membranous staining intensity), both assays overpredicted FRα positivity compared with the FOLR1 CDx in archival ovarian tumor samples.These data highlight the need for caution in antibody selection when developing immunohistochemistry-based assays, as some antibodies failed to cleanly and specifically identify FRα expression. We identified 2 antibodies appropriate for further investigation; however, as developed, these antibodies may overselect patients for treatment with FRα-targeted therapies.© 2025 College of American Pathologists.
Showing 1-4 of 420 papers.
Powered by BizGenius
 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
FOLR1靶点信息
英文全称:Folate receptor alpha
中文全称:叶酸受体α
种类:Homo sapiens
上市药物数量:3详情
临床药物数量:20详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定